A new interim analysis finds more evidence that ibrutinib plus rituximab is a viable option for younger patients with untreated chronic lymphocytic leukemia compared with standard chemoimmunotherapy.
Many patients with locally advanced rectal cancer can skip radiotherapy to the pelvic area, and instead be treated with chemotherapy and then surgery, suggest the results from the PROSPECT trial.
Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.